Market News AIOpen the app

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

TrialRead the original at globenewswire.com
Good for VALN

Valneva’s S4V2 studies showed favorable safety and promising efficacy signals, supporting a stronger outlook. The full results are still under review, so the company has not yet chosen the next development plan.

VALN · Valneva SE

AI read · Good for VALN

The AI's read

These findings give Valneva early evidence about a vaccine for a disease that causes many child deaths. The studies showed safety and efficacy signals, not confirmed protection in everyday use. Valneva is still reviewing the full results before choosing the candidate’s next development plan.

Get alerts for VALN

Follow Valneva SE (VALN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VALN
Free on the App Store and Google Play, or on the web.